Trials / Completed
CompletedNCT01503151
Cognitive Biases Modification Treatment for Social Anxiety
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Tel Aviv University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Adults with Social Phobia will be randomly assigned to either an attention bias modification treatment, interpretation bias modification treatment, both, or a placebo control condition not designed to change cognitive bias patterns. Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social phobia disorder and symptom counts derived from structured clinical interviews based on DSM-IV criteria. The investigators expect to find significant reduction in social anxiety symptoms in the Treatment groups relative to the placebo control group. The investigators want to find out the relative efficacy of attention and interpretation oriented treatments and the combination of the two.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Attention Bias Modification Treatment (ABMT) | Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns. |
| BEHAVIORAL | Interpretation Bias Modification (IBM) | Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias. |
| BEHAVIORAL | Control Condition | Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns. |
| BEHAVIORAL | Attention and Interpretive biases modification (CBM) | Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-01-02
- Last updated
- 2014-12-02
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01503151. Inclusion in this directory is not an endorsement.